Is Vyome Holdings, Inc. (HIND) overvalued? · rev $8.0M
Vyome Holdings, Inc. (HIND) is a biotechnology company listed on NASDAQ.
This page asks whether Vyome Holdings, Inc. (HIND) looks expensive on cached numbers — not a short thesis.
Latest reported HIND revenue for 2024-12-31 was $8.0M. Net income was -$7.1M. Revenue was down 7.7% from 2023-12-31 to 2024-12-31. HIND currently screens at market cap $16.1M.
HIND currently screens at market cap $16.1M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next HIND 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the HIND stock page for the full model, not this heading.
Not investment advice.